Dr. Michael O. Barry, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 2,354
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of Missouri, Columbia School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
FL license ME98323 -
Cardiac Rehabilitation Registered Nurse
FL license ME98323
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
- Morton Plant Hospital Clearwater, FL
Medical groups
- Morton Plant Health Services Inc (87 clinicians)
- Clearwater Cardiovascular and Interventional Consultants MD PA (39 clinicians)
- Pinellas Ekg Interpreters Inc (37 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,354
- Services billed
- 24,803
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 17,700 | 164 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,231 | 752 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 715 | 639 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 471 | 468 |
| Injection, regadenoson, 0.1 mg | 464 | 116 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 453 | 204 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 431 | 355 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 240 | 173 |
| Established patient office or other outpatient visit, 20-29 minutes | 236 | 219 |
| Blood test, clotting time | 234 | 142 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amlodipine Besylate Other prescribers in Clearwater, FL | 519 |
| Atorvastatin Calcium Other prescribers in Clearwater, FL | 514 |
| Metoprolol Succinate Other prescribers in Clearwater, FL | 452 |
| Eliquis (apixaban) Other prescribers in Clearwater, FL | 444 |
| Rosuvastatin Calcium Other prescribers in Clearwater, FL | 406 |
| Metoprolol Tartrate Other prescribers in Clearwater, FL | 400 |
| Lisinopril Other prescribers in Clearwater, FL | 344 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Clearwater, FL | 332 |
| Losartan Potassium Other prescribers in Clearwater, FL | 319 |
| Carvedilol Other prescribers in Clearwater, FL | 288 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 43 payments worth $2,293 in total to this clinician.
| Edwards Lifesciences Corporation | $1,868 |
|---|---|
| Pfizer Inc. | $162 |
| E.r. Squibb & Sons, L.l.c. | $157 |
| Abbott Laboratories | $58.94 |
| Boston Scientific Corporation | $18.19 |
| Medtronic, Inc. | $14.78 |
| AstraZeneca Pharmaceuticals LP | $14.31 |
| Travel and Lodging | $1,219 |
|---|---|
| Food and Beverage | $1,070 |
| Education | $3.20 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Edwards Lifesciences Corporation Sep 4, 2025 | Travel and Lodging EVOQUE · Transcatheter Valve Repair · travel to Chicago, IL · in-kind | $385 |
| Edwards Lifesciences Corporation Sep 9, 2025 | Travel and Lodging EVOQUE · Transcatheter Valve Repair · travel to Chicago, IL · in-kind | $351 |
| Edwards Lifesciences Corporation Aug 4, 2025 | Travel and Lodging EVOQUE · Transcatheter Valve Repair · travel to Chicago, IL · in-kind | $267 |
| Edwards Lifesciences Corporation Sep 11, 2025 | Travel and Lodging EVOQUE · Transcatheter Valve Repair · travel to Chicago, IL · in-kind | $172 |
| Abbott Laboratories Jan 6, 2025 | Travel and Lodging TRICLIP · Structural Heart · travel to Austin, TX · in-kind | $44.00 |
| Pfizer Inc. Apr 8, 2025 | Education VYNDAMAX · CARDIOVASCULAR · in-kind | $3.20 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $58,388 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc. - A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.